Investor Presentaiton

Cardiovascular milvexian Camzyos MYK-224 Opportunity to develop medicines in important Cardiovascular indications Asset Approved CAMZYOS™ (mavacamten) capsules 15mg Obstructive Hypertrophic Cardiomyopathy milvexian MYK-224 danicamtiv Ill Bristol Myers Squibb™ † ongoing or initiating 2023/2024 Registrational+ Non-obstructive Hypertrophic Cardiomyopathy Secondary Stroke Prevention Acute Coronary Syndrome Atrial Fibrillation Exploratory/PoC Studies* • Obstructive Hypertrophic Cardiomyopathy • Heart Failure with preserved Ejection Fraction Dilated cardiomyopathy Not for Product Promotional Use 112

View entire presentation